About Retrotope
Retrotope is a company based in Los Altos (United States) founded in 2006 by Mikhail S Shchepinov and Charles Cantor.. Retrotope has raised $58.58 million across 7 funding rounds from investors including MP Advisors, Timur Artemev and Morningside China. Retrotope offers products and services including RT001 and RT011. Retrotope operates in a competitive market with competitors including Harmony Biosciences, QurAlis, Passage Bio, Evox Therapeutics and Remegen, among others.
- Headquarter Los Altos, United States
- Founders Mikhail S Shchepinov, Charles Cantor
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Retrotope Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$58.58 M (USD)
in 7 rounds
-
Latest Funding Round
$13.3 M (USD), Series D
Jan 13, 2021
-
Investors
MP Advisors
& 6 more
-
Employee Count
Employee Count
-
Acquired by
(Jul 29, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Retrotope
Retrotope offers a comprehensive portfolio of products and services, including RT001 and RT011. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Stabilized Linoleic Acid for treating infantile neuroaxonal dystrophy and other diseases.
Stabilized Docosahexaenoic acid for dry age-related macular degeneration.
Unlock access to complete
Unlock access to complete
Funding Insights of Retrotope
Retrotope has successfully raised a total of $58.58M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $13.3 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series D — $13.3M
-
First Round
First Round
(24 Mar 2016)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series D - Retrotope | Valuation |
investors |
|
| Jul, 2019 | Amount | Series C - Retrotope | Valuation |
investors |
|
| Jul, 2019 | Amount | Series C - Retrotope | Valuation | Timur Artemev , MP Advisors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Retrotope
Retrotope has secured backing from 7 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include MP Advisors, Timur Artemev and Morningside China. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences startups are funded by a non-profit angel network.
|
Founded Year | Domain | Location | |
|
Early-stage companies are supported through angel investment funding.
|
Founded Year | Domain | Location | |
|
Early-stage venture capital investments are made in medical startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Retrotope
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Retrotope
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Retrotope Comparisons
Competitors of Retrotope
Retrotope operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harmony Biosciences, QurAlis, Passage Bio, Evox Therapeutics and Remegen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics for rare neurological diseases
|
|
| domain | founded_year | HQ Location |
Drugs and CSF devices are developed for ALS treatment.
|
|
| domain | founded_year | HQ Location |
Gene therapies for CNS rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Exosome-based gene therapies for neurological diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Psychedelic-based therapies for brain health disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Retrotope
Frequently Asked Questions about Retrotope
When was Retrotope founded?
Retrotope was founded in 2006 and raised its 1st funding round 10 years after it was founded.
Where is Retrotope located?
Retrotope is headquartered in Los Altos, United States. It is registered at Los Altos, California, United States.
Is Retrotope a funded company?
Retrotope is a funded company, having raised a total of $58.58M across 7 funding rounds to date. The company's 1st funding round was a Series C of $20M, raised on Mar 24, 2016.
What does Retrotope do?
Founded in 2006 and headquartered in Los Altos, United States, therapeutics are developed by Retrotope to address neurodegenerative and ophthalmological diseases. A proprietary drug discovery platform is utilized to produce disease-modifying drugs that target oxidative stress and cellular degeneration from lipid peroxidation. Lead candidates include RT001 for infantile neuroaxonal dystrophy, Friedreichs ataxia, and amyotrophic lateral sclerosis, alongside RT011 for dry age-related macular degeneration and geographic atrophy.
Who are the top competitors of Retrotope?
Retrotope's top competitors include Harmony Biosciences, QurAlis and MindMed.
What products or services does Retrotope offer?
Retrotope offers RT001 and RT011.
Who are Retrotope's investors?
Retrotope has 7 investors. Key investors include MP Advisors, Timur Artemev, Morningside China, Life Science Angels, and North Texas Angel Network.